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Aims This study aims to provide an overview on contemporary gender differences in the risk factor control of coronary




Analyses were based on the cross-sectional ESC (European Society of Cardiology) EORP (EurObservational
Research Programme) EUROASPIRE V (European Survey of Cardiovascular Disease Prevention and Diabetes)
survey including data on CHD patients across 27 European countries. Men and women between 18 and 80 years
old, hospitalized for a first or recurrent coronary event were included in the study. Data were available for
8261 patients of which 25.8% women. Overall, women had a worse risk factor control compared with men.
Whereas women were more likely to be non-smokers (79.3% vs. 87.2%; P < 0.001), they were less likely to reach
recommended levels of physical activity (36.8% vs. 27.5%; P < 0.001), and they were less likely to be non-obese
(65.1% vs. 54.3%; P < 0.001). There is indication that risk factors such as smoking behaviour and obesity differed de-
pending on country income level. No gender differences could be observed in blood pressure on target (P > 0.05).
Moreover, a lower proportion of women reached low-density lipoprotein cholesterol (LDL-C) target levels (31.4%
vs. 22.1%; P < 0.001), and they were less likely to reach glycated haemoglobin (HbA1c) targets if having
self-reported diabetes (56.7% vs. 48.6%; P < 0.001).
...................................................................................................................................................................................................
Conclusion The risk factor control of CHD women is substantial worse compared with men despite little gender differences in
cardiovascular medication intake. Further actions are needed to increase the awareness of the worse risk factor
control in female CHD patients.
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Introduction
Cardiovascular disease (CVD) remains the leading cause of mortality
and morbidity across Europe, with about 47% of women and 39% of
men dying from CVD.1 In response, the European Society of
Cardiology and Other Societies on Cardiovascular Disease
Prevention in Clinical Practice (Joint European Societies—JES) pro-
vide regularly updated recommendations to prevent CVD by guiding
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healthcare professionals in their daily clinical practice.1,2 The main
objectives of these guidelines are to reduce CVD mortality and mor-
bidity, to reduce events, and to improve patients’ quality of life.2
Despite substantial efforts to promote the importance of risk factor
management in patients with coronary heart disease (CHD), an un-
acceptably large amount of patients do not reach the recommended
risk factor targets.3–5 Previous large-scale studies reporting on risk
factor management suggest an even worse risk factor profile among
female patients, despite gender-neutral recommendations.6–8
Women were less likely to reach adequate levels of physical activity,
they were more frequently obese, and they were more likely to have
a history of diabetes.6,8 Women were also less likely to reach risk
factors targets for glycated haemoglobin (HbA1c) and low-density
lipoprotein cholesterol (LDL-C). In contrast, women were more like-
ly to be non-smokers.6,8 This gender gap in risk factor occurrence is
of paramount interest, especially since risk factors like smoking and
diabetes may have an even more detrimental effect in female
patients.9,10 The aim of this study was to provide an overview on con-
temporary gender differences in risk factor control of CHD patients
across Europe. Analyses were based on data from the latest
EUROASPIRE V survey. A particular focus is given to the stratification
of risk factors by country income level, to investigate whether there
are gender differences according to gross national income.
Methods
The cross-sectional ESC (European Society of Cardiology) EORP
(EurObservational Research Programme) EUROASPIRE V survey was
conducted in 2016–2017 to evaluate the implementation of the Joint
European Societies Guidelines (2016) on Cardiovascular Disease
Prevention in daily clinical practice2 in coronary patients. Detailed infor-
mation on the study design and methodology has been reported else-
where.4 Within each country, at least one geographical area with a
defined population was selected. A total of 131 centres were included,
covering 27 countries (Belgium, Bosnia and Herzegovina, Bulgaria,
Croatia, Czech Republic, Egypt, Finland, Germany, Greece, Ireland, Italy,
Kazakhstan, Kyrgyzstan, Latvia, Lithuania, The Netherlands, Poland,
Portugal, Romania, Russian Federation, Serbia, Slovenia, Spain, Sweden,
Turkey, Ukraine, and the UK). Consecutive patients (men and women),
between 18 and 80 years old at the time of identification, were retro-
spectively identified from diagnostic registers, hospital discharge lists, or
other sources. Patients eligible for inclusion had to be hospitalized for an
elective or emergency coronary artery bypass grafting (CABG), an elect-
ive or emergency percutaneous coronary intervention (PCI), an acute
myocardial infarction (AMI; ICD-10 I21), or an acute myocardial ischae-
mia (ICD-10 I20) at least 6 months and not more than 2 years prior to
the date of the study visit. Local research ethics committee approval for
each participating centre was obtained. Written informed consent was
completed by each participant. Data were submitted to the data manage-
ment centre EURObservational Research Program (EORP), ESC, Sophia-
Antipolis, France. Data collection was undertaken by centrally trained
research staff using standardized methods and instruments. Information
on patient’s demographics, risk factor profile, and disease management
was obtained from medical records, patient interviews, medical examin-
ation, and venous (fasting) blood sample using standardized methods and
instruments. Blood samples were centrally analysed by the Biochemistry
Laboratory in the National Institute of Health and Welfare (Helsinki,
Finland).
Variables and definitions
The Sixth Joint European Society guidelines (2016) were used to define
the risk factor targets.2 Current smoking was defined as self-reported
smoking and/or a breath carbon monoxide >10 ppm. Smoking cessation
was defined as non-smoking at time of the interview among those who
smoked in the month before the recruiting event. A recommended level
of physical activity was defined as regularly physical activity for at least
30 min, five times or more a week. Obesity was defined as a body mass
index (BMI) >_30 kg/m2. Blood pressure was measured twice on the right
upper arm in a sitting position using an automatic digital sphygmomanom-
eter. The mean of both measurements was used for analyses. Targets for
blood pressure were set at systolic/diastolic blood pressure (SBP/DBP)
<140/90 mmHg (<140/85 mmHg in patients with diabetes). ‘Controlled
hypertension’ was used to indicate blood pressure levels on target in
patients treated with anti-hypertensive medication. Venous (fasting)
blood samples were taken to analyse LDL-C, high-density lipoprotein
cholesterol (HDL-C), and HbA1c levels. The LDL-C was calculated
according to the Friedewald’s formula.11 Targets for LDL-C levels was
defined as an LDL-C <1.8 mmol/L. ‘Controlled dyslipidaemia’ was used to
indicate LDL-C levels on target in patients treated with lipid-lowering
drugs. HbA1c level targets were defined as <7% in patients with
self-reported diabetes and <6.5% in patients without diabetes. Previous
hospitalization for stroke, heart failure, CABG/PCI, and peripheral artery
disease (PAD) were defined as ever being hospitalized for a stroke, heart
failure, CABG/PCI, and PAD, respectively. Information on cardiovascular
medication intake was based on medication use at the time of the study
visit (patients were asked to bring their medication with them during
study visit).
Educational level was divided into three categories: primary education
(no formal school, less than primary school, or primary school com-
pleted), secondary education (secondary school completed, high school
completed, or intermediate between secondary level), and high educa-
tion (College/University completed or post-graduate degree). In addition,
countries were grouped in two categories according to their gross
national income per capita using the World Bank Atlas method12:
high-income countries (Belgium, Croatia, Czech Republic, Finland,
Germany, Greece, Ireland, Italy, Latvia, Lithuania, Poland, Portugal,
Slovenia, Spain, Sweden, The Netherlands, and UK) and middle-income
countries (Bosnia and Herzegovina, Bulgaria, Egypt, Kazakhstan,
Kyrgyzstan, Romania, Russian Federation, Serbia, Turkey, and Ukraine).
Statistical analysis
Descriptive statistics were used, stratified by gender, to describe patients’
characteristics, the risk factor profile, and the information provided by
health care professionals about patients’ risk factor control. Logistic
regression analyses were performed adjusted for age at interview
(continuous), history of stroke, history of heart failure, and self-reported
diabetes. The association between gender and the risk factor profile was
expressed as odds ratios (ORs) and their 95% confidence intervals (CIs).
The threshold indicating statistical significance was set at P < 0.05. All stat-
istical analyses were performed with IBM SPSS Statistics 25 software.
Results
Patient characteristics
Data from 8261 patients were available, of which 25.8% were
women. On average, women were significantly older at the time of
the study visit and had a lower educational level compared with men.
Furthermore, women were more likely to have a history of stroke,

































































































a history of heart failure, and self-reported diabetes. Previous hospi-
talization for CABG or PCI was less frequent in women compared
with men. In addition, patients recruited from middle-income coun-
tries were more often females. A detailed overview of the patient
characteristics is given in Table 1.
Risk factor profile
Table 2 provides an overview of patients’ risk factor profile, stratified
by gender. Overall, women were significantly more likely to be non-
smokers. Also, the prevalence of smoking before the recruiting event
was lower in women compared to men. No gender differences could
be observed in smoking cessation. Interestingly, there is some indica-
tion that smoking behaviour differed across country income. A signifi-
cant gender by country income interaction effect was found for
smoking behaviour (P < 0.001). Stratification by country revealed a
trend to significant gender differences in middle-income countries
but not in high-income countries (Figure 1A). Furthermore, women
were less likely to have adequate levels of physical activity. This find-
ing was mostly consistent across countries (Figure 1B). Also, signifi-
cant gender differences in disfavour of women were seen regarding
the prevalence of non-obese patients. As shown in Figure 1C, gender
differences in the prevalence of non-obese patients vary between
countries. A significant gender by country income interaction effect
was found for being non-obese (P = 0.001). Especially in middle-
income countries, the odds of being non-obese are lower in women
compared with men. Overall, no gender differences could be
observed regarding blood pressure on target although gender differ-
ences varied substantially between counties (Figure 1D). Whereas no
gender differences could be observed for treated hypertension
(46.3% vs. 46.6%; P = 0.43), women were less likely to have uncon-
trolled hypertension (30.0% vs. 23.5%; P = 0.004). Interestingly,
women were more likely to use anti-hypertensive medication
(Table 2). Furthermore, women were less likely to have their LDL-C
on target. Also, women were less likely to use lipid-lowering medica-
tion (Table 2). Both for treated (65.9% vs. 74.3%; P = 0.001) and un-
treated (85.4% vs. 91.8%; P < 0.001) patients, women were less likely
to reach the LDL-C risk factor target. This pattern was quite homo-
geneous across countries (Figure 1E). Among patients with self-
reported diabetes, women were less likely to reach the HbA1c level
target. No gender differences could be observed in HbA1c level
targets in patients without diabetes. Supplementary material online,
Table S1 provides an overview of the combinations of risk factors.
The combination of non-smoking, non-obese, and blood pressure on
target was most common in both men and women.
Discussion
The importance of risk factor control in patients with CHD is widely
documented.13–15 However, previous research on risk factor man-
agement reported a large proportion of CHD patients who do not
reach guidelines recommended risk factor targets, especially in fe-
male patients.16,17 Overall, our study confirms previous study findings
showing a worse risk factor control in female patients. Despite the
fact that women smoked less, they were more likely to be physically
inactive and a higher proportion of them were obese. Interestingly,
no gender difference was observed in the control of blood pressure,
although women used anti-hypertensive medication more often.
Furthermore, LDL-C control was worse in women compared with
men and women were less likely to use lipid-lowering drugs.
Moreover, less women with diabetes reached the HbA1c target.
Previous studies suggest that more comorbidities due to a later age
of CHD onset in women and a possible lack of awareness among
healthcare professionals and female patients concerning CHD in
women resulting in delayed diagnosis, could partly explain this risk
profile gender gap.9,18 Several studies reported on gender differences
in the risk factor management of CHD patients, in disfavour of
women.19–21 For instance, the VIRGO (Variation in recovery: Role of
Gender on Outcomes of Young AMI Patients) study, including 3501
AMI patients, observed more diabetes and obesity in women com-
pared with men.22 Also, the SWEDEHEART (Swedish Web System
for Enhancement and Development of Evidence-Based Care in the
Heart Disease Evaluated According to Recommended Therapies)
registry, based on 51 620 AMI patients, reported on gender differen-
ces regarding blood pressure control and LDL-C targets, in disfavour
of women.7 Moreover, the REACH Registry, based on 19 105
patients with documented arterial disease, reported that women
were more likely to have elevated cholesterol levels and more
women were obese.23 Furthermore, the previous EUROASPIRE IV
survey, conducted in 7998 coronary artery disease patients demon-
strated that more women had a higher prevalence of obesity and
they were less likely to have adequate levels of physical activity, LDL-
C on target, and an HbA1c on target (in patients with self-reported
diabetes).6 In an attempt to reduce these gender differences, several
actions at the population level are taken to improve the awareness of
CHD in female patients, such as ‘Go Red for Women’, an annual
international awareness campaign initiated in 2004 to increase the
awareness of CVD in women and which was endorsed by The
World Heart Federation. The aim is to empower female patients to
take charge of their own heart health.24 Moreover, over 50 countries
are running campaigns among healthcare professionals and the gen-
eral public in order to increase the awareness of CVD in women.24
Since individual behaviour is influenced by family, culture, and local
policies, a population-wide strategy may be more successful in bridg-
ing the gender gap in cardiovascular disease burden.2
In continuation of previous research and the numerous awareness
campaigns, the aim of this study was to provide a contemporary over-
view on potential gender differences in risk factor control in CHD
patients, based on data from the most recent EUROASPIRE V survey.
Despite several actions in order to reduce the CVD burden in
women, our study results largely confirm previous research, showing
substantial gender differences in the risk factor control of CHD
patients. The implementation of the JES guidelines on risk factor tar-
get management in secondary prevention is suboptimal, especially in
women. As reported in previous studies, women in this study were
more likely to be non-smokers.6,25 In this study, a remarkable gender
difference was found. Analyses stratified by country revealed a trend
to significant gender differences in middle-income countries but not
in high-income countries. A possible explanation could be that there
are increased smoking rates in female patients, especially in younger
women from high-income countries.16 However, these results
should be interpreted with caution because EUROASPIRE centres
may be not representative for the entire country. Interestingly, no













..gender differences could be observed in smoking cessation.
Moreover, women were more likely to be obese and have inad-
equate levels of physical activity. Also, women had a higher
prevalence of self-reported diabetes and they were less likely to
reach HbA1c level targets if having diabetes. Evidence suggests a
growing burden of obesity, which may have an impact on other risk
....................................................................................................................................................................................................................
Table 1 Patient’s characteristics
Men (n 5 6132) Women (n 5 2129) P-value
Age, mean (SD) 63.0 (9.7) 65.4 (9.2) <0.001a
Educational level, % (n) <0.001b
Primary 13.9% (834) 18.2% (383)
Secondary 58.4% (3514) 56.1% (1179)
High 27.7% (1669) 25.6% (538)
Country income level, % (n) <0.001b
High 59.8% (3666) 53.6% (1142)
Middle 40.2% (2466) 46.4% (987)
Previous hospitalization, % (n)
CABG 20.4% (1253) 13.2% (282) <0.001c
PCI 82.1% (5035) 74.9% (1594) <0.001c
Stroke 3.7% (229) 5.3% (112) 0.04c
Heart failure 5.9% (362) 7.6% (162) 0.02c
Peripheral artery disease 2.7% (167) 2.5% (54) 0.25c
Self-reported diabetes 28.0% (1703) 33.1% (697) <0.001c
Country <0.001b
Belgium 3.0% (183) 1.8% (39)
Bosnia and Herzegovina 2.6% (159) 2.3% (49)
Bulgaria 4.1% (249) 4.9% (104)
Croatia 5.0% (304) 4.4% (94)
Czech Republic 5.0% (306) 4.7% (100)
Egypt 3.9% (240) 5.1% (108)
Finland 1.9% (119) 3.1% (66)
Germany 5.2% (319) 3.4% (73)
Greece 1.5% (94) 1.2% (25)
Ireland 4.0% (248) 2.4% (51)
Italy 2.4% (147) 1.6% (34)
Kazakhstan 4.6% (285) 6.2% (132)
Kyrgyzstan 3.6% (219) 6.5% (139)
Latvia 1.6% (97) 1.9% (41)
Lithuania 4.5% (278) 5.4% (116)
The Netherlands 2.5% (155) 1.8% (38)
Poland 4.7% (288) 5.4% (116)
Portugal 3.8% (231) 3.0% (64)
Romania 4.8% (293) 5.0% (106)
Russian Federation 4.7% (291) 5.1% (108)
Serbia 4.1% (250) 4.0% (85)
Slovenia 1.7% (103) 2.2% (46)
Spain 4.5% (276) 3.9% (83)
Sweden 3.3% (201) 2.6% (55)
Turkey 3.1% (188) 2.2% (46)
Ukraine 4.8% (292) 5.2% (110)
UK 5.2% (317) 4.8% (103)




cLogistic regression adjusted for age.
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Table 2 Modifiable risk factors and their control at the time of interview
All countries Men Women P-value Odds ratio (95% CI)
(women vs. men)
Smoking
Non-smoking 79.3% (4863) 87.2% (1857) <0.001 1.57 (1.36–1.82)
Smoking cessation 45.8% (967) 43.5% (186) 0.32 0.90 (0.73–1.11)
Physical activity
Recommended levels of physical activitya 36.8% (2051) 27.5% (516) <0.001 0.69 (0.61–0.77)
Body weight
Non-obeseb 65.1% (3935) 54.3% (1127) <0.001 0.63 (0.57–0.70)
Blood pressure
BP on targetc 57.9% (3524) 57.4% (1208) 0.24 1.06 (0.96–1.18)
Anti-hypertensive medication 75.7% (4488) 83.1% (1722) <0.001 1.44 (1.26–1.64)
Cholesterol
LDL-cholesterol on targetd 31.4% (1767) 22.1% (433) <0.001 0.59 (0.52–0.67)
Lipid-lowering medication 85.6% (5188) 80.1% (1684) <0.001 0.66 (0.58–0.75)
HbA1C
HbA1c <7%e 56.7% (918) 48.6% (314) <0.001 0.70 (0.58–0.84)
HbA1c <6.5%e 95.3% (4007) 95.2% (1285) 0.75 0.95 (0.71–1.27)
Logistic regression adjusted for sex, age, stroke, heart failure, and self-reported diabetes. These bold values were to show that the result is significant (P<0.05).
BP, blood pressure; HbA1c, glycated haemoglobin; LDL-cholesterol, low-density lipoprotein.
aPhysical activity more than 30 min for five times/week.
bBMI <30 kg/m2.
cBlood pressure <140/90 (<140/85 if diabetes).
dLDL-cholesterol <1.8 mmol/L.
eHbA1c <7% if having self-reported diabetes, HbA1c <6.5% if having no self-reported diabetes.
A B C
Figure 1 Risk factor profile. (A) Non-smoking. (B) Adequate physical activity. (C) Non-Obesea. (D) Blood pressure on targetb. (E) Low-density
lipoprotein cholesterol on targetc. Logistic regression adjusted for sex, age, stroke, heart failure, and diabetes. This figure includes log odds ratios
(95% CI) presented as women vs. men. Countries in bold are middle-income countries. aBMI <30 kg/m2. bBlood pressure <140/90 (<140/85 if having
diabetes). cLDL-C <1.8 mmol/L.




















































..factors, such as raised blood pressure and diabetes.4,26 It is possible
that women were more likely to have diabetes due to the higher
prevalence of obesity, which can partly explain these findings.
Furthermore, women were less likely to reach LDL-C level targets.
These findings are in line with the SURF (Survey of Risk Factors)
study, based on 10 112 CHD patients (2012–13).8 A possible explan-
ation could be that there is insufficient evidence about the effective-
ness of evidence-based medications in women.8,27 Evidence-based
guidelines are based on large clinical trials, which are typically domi-
nated by male participants.16 Interestingly, as shown in our study,
women were less likely to use lipid-lowering medication at the time
of the study visit. Previous research confirmed this findings, reporting
that women were less likely to be treated with statins which can part-
ly explain this gender difference in LDL-C control.7 Also, women are
less likely to adhere to statins because of more side effects.28 Similar
to previous studies (EUROASPIRE IV, the VIRGO-study) no gender
differences could be observed in the overall blood pressure con-
trol.6,29 Remarkably, women were more likely than men to use anti-
hypertensive medication at the time of the study visit.
It has to be underlined that previous EUROASPIRE analyses
regarding gender differences in medical treatment revealed little to
no gender differences.6,30 The risk factor profile of female patients
remains suboptimal. There are several possible explanations for the
worse risk factor control in female patients diagnosed with CHD.
First, as suggested in the INTERHEART study, women developed
CHD on average 10 years later compared with men. Women may
therefore have a lower risk factor burden at younger age.31 This
might be partly explained by the protective effect of oestrogens.32
Due to the older age of onset, women may already have a worse risk
factor profile before the recruiting event, which may result in a
greater effort needed to bring them on target. Further research
should focus on existing gender differences in primary prevention,
which can explain this gender gap.33,34 Moreover, research suggests
that women were less likely to be told by a healthcare professional
that they were at risk.22 In addition, women were more likely to have
anxiety and depression, which were associated with a higher preva-
lence of risk factors like inadequate levels of physical activity and
obesity.35,36 This could be a possible explanation for the lower levels
of physical activity and a higher prevalence of obesity in women.
A major strength of the EUROASPIRE surveys is that data are
based on standardized methods and equipment, including central la-
boratory analyses. Therefore, we believe the EUROASPIRE V survey
provides reliable information on the actual risk factor profile of cor-
onary patients in Europe. Although our study provides an up to date
overview on the risk factor control of CHD patients, some limita-
tions should be mentioned. Not all geographical areas within each
country were selected by the national principal investigators and may
therefore not be representative for the entire country. The average
EUROASPIRE V interview participation rate was low (56%).
Non-participants may have a worse lifestyle and a poorer risk factor
control.
Conclusion
In conclusion, although risk factor management is a major component
in CHD care in both genders, our results suggest substantial gender
D E
Figure 1 Continued.

































































































differences for secondary prevention, mostly in disfavour of women.
Despite the fact that previous EUROASPIRE findings suggest that
there are only limited gender differences in the medical treatment of
CHD patients, this was not reflected in their risk factor profile.
Actions are needed to further elucidate this gender-differential in risk
factor control.
Supplementary material
Supplementary material is available at European Journal of Preventive
Cardiology online.
Acknowledgements
Registry Executive Committee and Steering Committee of the
EURObservational Research Programme (EORP). Data collection
was conducted by the EORP department from the ESC by Emanuela
Fiorucci as Project Officer, Viviane Missiamenou, and Florian Larras
as Data Manager. All investigators are listed in Supplementary mater-
ial online, Appendix S1. The EUROASPIRE Study Group is grateful to
the administrative staff, physicians, nurses and other personnel in the
hospitals in which the survey was carried out and to all patients who
participated in the surveys.
Funding
The EUROASPIRE V survey was carried out under the auspices of the
European Society of Cardiology, EURObservational Research Programme
(EORP). Since the start of EORP, the following companies have
supported the programme: Amarin, Amgen, Daiichi Sankyo, Elli Lily,
Ferrer, Novo Nordisk, Pfizer, and Sanofi. The sponsors of the EuroAspire
surveys had no role in the design, data collection, data analysis, data
interpretation, decision to publish, or writing the manuscript. P.V. is
financially supported by the ‘Fonds voor Hartchirurgie—Fonds pour la
Chirurgie Cardiaque’.
Conflict of interest: The authors declare that there is no conflict of
interest.
References
1. Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, Mossialos
EA, Maggioni AP, Kazakiewicz D, May HT, De Smedt D, Flather M, Zuhlke L,
Beltrame JF, Huculeci R, Tavazzi L, Hindricks G, Bax J, Casadei B, Achenbach S,
Wright L, Vardas P; European Society of Cardiology. European Society of
Cardiology: cardiovascular disease statistics 2019. Eur Heart J 2020;41:12–85.
2. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney M-
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